InnoSIGN

Executive Summary

InnoSIGN is a Netherlands-based diagnostics company developing OncoSIGNal, a pathway activity profiling platform that translates tumor molecular data into functional insights on cell behavior. This enables next-generation precision oncology by improving patient stratification and treatment selection. Founded in 2016, the company is at a pre-clinical stage, focusing on validating its technology through collaborations and studies. With a novel approach that goes beyond static genomics, InnoSIGN aims to address current limitations in predicting therapy response. The company's potential is underscored by the growing demand for functional biomarkers in oncology. However, as an early-stage venture, it faces risks related to validation, regulatory approval, and competition. Near-term value drivers include fundraising, partnerships, and initial clinical data. The company is positioned to attract strategic interest from pharmaceutical firms seeking to enhance their drug development pipelines.

Upcoming Catalysts (preview)

• Q3 2026Series A funding round70% success
• Q3 2026Pharma partnership for OncoSIGNal validation60% success
• Q4 2026First clinical data release from validation study50% success